We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+24.43%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$13.3B
AUM Growth
-$343M
(-2.5%)
Cap. Flow
-$2.51B
Cap. Flow
% of AUM
-18.9%
Top 10 Holdings %
Top 10 Hldgs %
48.31%
Holding
117
New
19
Increased
28
Reduced
28
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$737M |
| 2 |
S&P Global
SPGI
|
+$177M |
| 3 |
Sherwin-Williams
SHW
|
+$160M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$145M |
| 5 |
GG
Goldcorp Inc
GG
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$616M |
| 2 |
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
|
+$370M |
| 3 |
Equinix
EQIX
|
+$283M |
| 4 |
Meta Platforms (Facebook)
META
|
+$194M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$193M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.15% |
| 2 | Technology | 20.49% |
| 3 | Communication Services | 16.9% |
| 4 | Industrials | 6.58% |
| 5 | Consumer Discretionary | 6.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
NovoCure
NVCR
$1.83B
| $50.6M | 0.38% |
1,050,000
-200,000
| -16% | -$9.63M |
|
|
KYNB
52
Kyntra Bio
KYNB
$28.3M
| $49.8M | 0.37% |
36,623
+6,623
| +22% | +$8.98M |
|
53
Walt Disney
DIS
$181B
| $48.9M | 0.37% |
+440,000
| New | +$49.2M |
|
54
NXP Semiconductors
NXPI
$58.4B
| $47.3M | 0.36% |
535,000
| – | – |
|
55
Alnylam Pharmaceuticals
ALNY
$28.9B
| $46.7M | 0.35% |
500,000
-50,000
| -9% | -$4.18M |
|
56
Fate Therapeutics
FATE
$290M
| $43.9M | 0.33% |
2,500,000
+300,000
| +14% | +$4.74M |
|
|
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
| $40.7M | 0.31% |
2,043,149
| – | – |
|
|
SINA
58
DELISTED
Sina Corp
SINA
| $38.5M | 0.29% |
+650,000
| New | +$39M |
|
59
Arrowhead Research
ARWR
$12.1B
| $35.2M | 0.27% |
1,920,609
+420,609
| +28% | +$6.94M |
|
60
CVS Health
CVS
$123B
| $33.7M | 0.25% |
625,000
-305,000
| -33% | -$18.8M |
|
|
RC
61
Ready Capital
RC
$279M
| $32.9M | 0.25% |
2,243,239
+40,000
| +2% | +$611K |
|
62
PTC Therapeutics
PTCT
$5.91B
| $26.3M | 0.2% |
700,000
| – | – |
|
63
Fox Class A
FOXA
$25.9B
| $26M | 0.2% |
+709,220
| New | +$27.6M |
|
64
CRISPR Therapeutics
CRSP
$4.99B
| $25.9M | 0.19% |
725,000
-525,000
| -42% | -$18.2M |
|
|
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
| $25.7M | 0.19% |
+2,000,000
| New | +$22.6M |
|
66
Codexis
CDXS
$159M
| $25.7M | 0.19% |
1,250,000
+95,000
| +8% | +$1.85M |
|
67
Zymeworks
ZYME
$1.7B
| $25.5M | 0.19% |
1,575,000
| – | – |
|
|
QTNT
68
DELISTED
Quotient Limited Ordinary Shares
QTNT
| – | – |
-60,000
| Closed | -$21.1M |
|
69
Protagonist Therapeutics
PTGX
$9.46B
| $22.5M | 0.17% |
1,790,000
-409,674
| -19% | -$3.62M |
|
|
CCXI
70
DELISTED
ChemoCentryx, Inc.
CCXI
| $20.8M | 0.16% |
1,500,000
+50,000
| +3% | +$572K |
|
|
TECX
71
Tectonic Therapeutic
TECX
$570M
| $19.8M | 0.15% |
75,000
+20,833
| +38% | +$3.81M |
|
|
PGNX
72
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $19.5M | 0.15% |
4,200,820
| – | – |
|
73
Voyager Therapeutics
VYGR
$189M
| $19.1M | 0.14% |
1,000,158
+91,000
| +10% | +$1.19M |
|
74
Savara
SVRA
$1.19B
| $17.9M | 0.13% |
2,425,000
| – | – |
|
|
BMS
75
DELISTED
Bemis
BMS
| $17.5M | 0.13% |
316,160
| – | – |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Farallon Capital Management held 117 positions worth $13.3B, down 2.5% from $13.6B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Farallon Capital Management withdrew a net $2.51B in Q1 2019, closing 22 positions and reducing 28 holdings. Its most notable exit was Twenty-First Century Fox, Inc. Class A, an estimated $616M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 20% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Celgene Corp worth $795M.
- Farallon Capital Management's largest Q1 2019 buy was Celgene Corp: 8,430,000 shares worth $795M.
- Farallon Capital Management added most to Red Hat Inc in Q1 2019, an estimated $116M increase.
- Farallon Capital Management's biggest Q1 2019 reduction was Equinix, cutting an estimated $283M.
- Farallon Capital Management fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $616M.
- Farallon Capital Management's ten largest holdings make up 48% of its $13.3B portfolio in Q1 2019.
- Farallon Capital Management opened 19 new positions and closed 22 in Q1 2019.
- Farallon Capital Management's portfolio value fell 2.5% quarter-over-quarter to $13.3B.
Based on Farallon Capital Management's 13F filing for Q1 2019, filed 15 May 2019.